This article first appeared on GuruFocus .
Release Date: August 12, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Dyadic International Inc ( NASDAQ:DYAI ) reported a 52% increase in total revenue for the first half of 2026, reaching $2.1 million.
-
The company achieved an 80% productivity improvement in its recombinant human transferrin program, reducing costs by approximately 40%.
-
Dyadic International Inc ( NASDAQ:DYAI ) initiated product shipments to IBT BioServices and generated initial pilot sales for cultivated meat applications.
-
The company's partner Proliant has begun commercializing Albufree DX and plans to launch additional products, potentially providing future royalties.
-
Dyadic International Inc ( NASDAQ:DYAI ) is advancing externally funded biopharmaceutical programs, including a $3 million Gates Foundation grant and a CEPI collaboration, demonstrating C1's rapid protein production capabilities.
Negative Points
-
Dyadic International Inc ( NASDAQ:DYAI ) reported a net loss of $2.1 million for Q2 2026, consistent with the prior year period.
-
The company's cost of revenue increased 60% year-over-year, driven by higher activity in grant-funded programs.
-
Dyadic International Inc ( NASDAQ:DYAI ) has substantial doubt about its ability to continue as a going concern, requiring additional capital within the next 12 months.
-
The company's cash position is only $4.8 million, and it is actively seeking financing alternatives, including potential dilution.
-
Product revenue ramp is expected to be lumpy and early-stage, with no clear timeline for significant recurring revenue.
Q & A Highlights
Q: Should we anticipate seeing product revenues in the third quarter, and will the ramp be lumpy over the first few quarters? A: Joe Hazelton (President and COO): Yes, lumpy would be the best way to describe it. In Q2, we began filling channels by shipping products to our first global distributor, IBT, and made direct pilot sales into cultured meat and research segments. It's too early to determine the ramp until we see recurring orders. However, partners like ProLiant are launching additional products, and Enzymes and Firmbox are also active, so we hope to build the ramp as quickly as possible.
Q: How are you prioritizing the many products and partnerships you are working on? A: Joe Hazelton (President and COO): It's prioritized based on revenuespecifically, the amount of revenue we can generate in the shortest amount of time. Whether it's a direct sale or a licensing opportunity, we focus on the size of the potential opportunity and execute accordingly.
Q: What are the intermediate steps between product shipments and Dyadic's top-line revenue? A: Joe Hazelton (President and COO): It depends on the shipment type. Direct customer shipments are direct sales, while shipments to distributors enter the channel and sell through. Partners like ProLiant generate revenue on the back end. We've placed six product opportunities into commercial distribution with IBT, and we need to ramp that up. The key is getting product into the market, and we're exploring additional distribution opportunities to grow.
Q: Can you provide any guidance on expected cash flows in the second half of the year, particularly regarding the Enzymes milestone? A: Mark Enosard (CEO): On the industrial biotech side, we're engaging with parties interested in using the DAPIBIS platform for enzymes and bio-based chemicals, with updates potentially in Q3. On the pharmaceutical side, data from the Gates Foundation MABS programs (RSV and malaria) is advancing well, and the 15-day plasmid-to-protein capability from CEPI is applicable across our portfolio. We're in discussions with major suppliers and pharmaceutical companies, hoping to land a large non-dilutive capital infusion that could last several months to several years. We previously brought in $30 million of non-dilutive capital, and one of these checks could make a huge difference.
Q: Can you elaborate on the 80% productivity improvement in the recombinant human transferrin program and its broader implications? A: Joe Hazelton (President and COO): The initial pilot scale run increased productivity by approximately 80%, which is expected to reduce costs by about 40% based on preliminary biomanufacturing assumptions. This improves commercial flexibility, scalability, and supply profile for customer qualification. Importantly, it also validates the broader C1 and DAPIBIS platforms, demonstrating our ability to manufacture proteins more efficiently and economically, which strengthens the case for larger strategic collaborations and licensing arrangements.
Q: What is the status of the biopharmaceutical programs, and how do they contribute to the broader business? A: Mark Enosard (CEO): Our biopharma strategy remains partner-funded and capital efficient. The Gates Foundation collaboration (approximately $3 million grant) is focused on monoclonal antibodies for RSV and malaria, with C1-produced antibodies showing high productivity and functional characteristics comparable to mammalian cell references. The CEPI-supported collaboration through FBS (up to $2.4 million) demonstrated the ability to progress from plasmid to purified protein antigen in approximately 15 days, applied to Ebola virus antigens. These programs generate data that strengthens C1's value proposition for potential licensing and strategic opportunities.
Q: Can you explain the going concern disclosure and what it means for the company's future? A: Peng Rawson (CFO): The going concern conclusion is a required accounting assessment under ASC 205-20, based on whether current resources and probable financing actions are sufficient to fund obligations over the 12-month look-forward period. It does not mean the company is ceasing operations, and we are in compliance with all covenants under our convertible notes, which don't mature until December 31, 2027. We are actively evaluating a range of financing alternatives, including non-dilutive sources like licensing arrangements, milestones, royalties, and funded development programs, to strengthen our balance sheet.
Q: What were the key financial results for Q2 2026, and how do they compare to the prior year? A: Peng Rawson (CFO): Total revenue for Q2 2026 was approximately $961,000, essentially flat compared to $967,000 in Q2 2025. For the first six months, revenue increased 52% to $2.1 million. Cost of revenue increased 60% to $984,000 due to higher grant-funded program activity. Internal R&D expenses decreased 47% to $333,000, reflecting disciplined spending. G&A expenses increased 18% to $1.7 million, driven by higher rebranding and business development costs. Net loss was $2.1 million or $0.06 per share, compared to $1.8 million or $0.06 per share in the prior year period.
Q: How is the company's distribution strategy evolving, and what role do partners play? A: Joe Hazelton (President and COO): Our distribution strategy is intentionally capital efficient. Rather than building a large direct commercial organization, we combine selective direct sales with distributors and OEM partners that have existing customer relationships and global reach. ProLiant has begun commercializing Albufree DX recombinant human albumin and plans to launch Albufree TX and Albufree CGT. Enzymes' non-animal bovine Cognosin is generating commercial sales, and Firmbox Bio has expanded commercialization around recombinant DNase 1 and transferrins. These relationships create multiple revenue pathways through direct sales, partner sales, milestones, royalties, and licensing.
Q: What progress has been made in the bioindustrial segment, particularly with the new cellulase products? A: Joe Hazelton (President and COO): In July, we announced new proprietary industrial cellulase products engineered for advanced fiber modification applications, including pulp biorefining, microcrystalline cellulose, and nanocellulose production. This program builds on the commercialization of N3Zyme and demonstrates DAPIBIS as a repeatable product development platform across multiple enzyme classes. The shared microbial production strains and development infrastructure help streamline strain development, process optimization, and scale-up as additional products move through the pipeline.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
